http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-095310-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b8726f713a6d86892687edccfa03d886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P33-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-08
filingDate 2014-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d27ec9e171fcbba7b57feb93db5da802
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0c56e6f24ec39ee3dcbd0162890c197
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7dfab71eb48592bb21c96d3ead6d2137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0dc7018c027b82f92e48bcb2cfef5f26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_050baae98dce131771a59289850e7172
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_208bc010b830d5520b6700604a8741b1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6566e63c8913bdcdfd3a2e5cf3e0c4d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41b564720804a4590119be794457c1d6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf9999377aab52db11a36e1b39483cf8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ed3459b6a1f7fc2f26f7c7e2123e5cc
publicationDate 2015-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber AR-095310-A1
titleOfInvention COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITARY DISEASES
abstract The present further provides pharmaceutical compositions comprising such compounds and methods of using such compounds to treat, prevent, inhibit, improve, or eradicate the pathology and / or symptomatology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease. Claim 1: A compound of the formula (1), or a pharmaceutically acceptable salt, or stereoisomer thereof; wherein Rˣ is hydrogen or C₁₋₄ alkyl; L¹ is a bond, CH₂C (O) -, -C (O) - or -S (O) ₂-; R¹ is selected from hydrogen, nitrogen, C₁₋₄ alkyl, C₁₋₄ alkenyl, C₁₋₆ alkoxy, amino, -NR⁷ᵃR⁷ᵇ, C₃₋₆ cycloalkyl, C₄₋₇ heterocycloalkyl, C₅₋₆ heterocycloalkenyl, phenyl, benzyl and heteroaryl C₅₋₉; or -NRˣL¹R¹ is nitrogen; or R¹ and Rˣ are taken together with the atoms to which R¹ and Rˣ are linked to form a C₄₋₉ heteroaricyclic substituted by 1 or 2 oxo, wherein R⁷ᵃ is hydrogen or C₁₋₄ alkyl; R⁷ᵇ is selected from hydrogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₆ alkoxy, amino, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl substituted by C₁₋₄ alkoxy, and C₅₋₆ heteroaryl, wherein the C₅₋₆ heteroaryl of R⁷ᵇ is optionally substituted by 1 to 2 substituents independently selected from halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy or amino; and wherein the hydrogens available in the C₁₋₄ alkyl of R⁷ᵃ and R⁷ᵇ are optionally replaced by deuterium; C₁₋₄ alkyl, C₁₋₄ alkenyl, C₁₋₆ alkoxy, amino, C₃₋₆ cycloalkyl, C₄₋₇ heterocycloalkyl, C₅₋₆ heterocycloalkenyl, phenyl, or C₅₋₉ heteroaryl of R¹ is optionally substituted by 1 to 4 substituents independently selected from hydroxyl, halogen, cyano, oxo, C₁₋₄ alkyl, C₁₋₄ hydroxyalkyl, C₁₋₄ haloalkyl, C₁₋₆ alkoxy, C halo haloalkoxy, C₁₋₄ alkylcarbonyloxy, hydroxycarbonyl, C₁₋₄ alkylcarbonyl, C₁₋₄ alkoxycarbonyl, aminocarbonyl, amino, C₁₋₄ alkylamino, C₁₋₄ alkylcarbonylamino, C₁₋₄-N-C-alkylaminocarbonyl, C₁₋₆ alkoxycarbonylamino, C₁₋₄-N-C₁₋₄ alkylaminocarbonyl, C₁ alkylsulfonyl ₋₄, C₃₋₆ cycloalkyl substituted by C₁₋₆ alkoxy, C₃₋₆ cycloalkyl, C₄₋₆ heterocycloalkyl, phenyl, and C₅₋₆ heteroaryl; wherein the C₃₋₆ cycloalkyl, C₄₋₆ heterocycloalkyl, C₅₋₆ heterocycloalkyl, phenyl or the C₅₋₆ heteroaryl substituent is further optionally substituted by 1 to 2 substituents independently selected from halogen, C₁₋₄ alkyl, C₁ alkylamino ₋₄, or C₄₋₆ heterocycloalkyl; R³ is selected from hydrogen, halogen, cyano, C₁₋₄ alkyl and C₁₋₄ haloalkyl; R⁴ is selected from hydrogen, halogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, and -C (O) R¹⁰, wherein R¹⁰ is selected from hydroxyl, C₁₋₄ alkyl, C₁₋₄ alkoxy, amino, C₁₋₄ alkylamino, C₃₋₆ cycloalkyl and C₄₋₆ heterocycloalkyl, wherein C₁₋₄ alkyl, C₁₋₄ alkoxy, amino, C₁₋₄ alkylamino, C₃₋₆ cycloalkyl or C₄₋₆ heterocycloalkyl of R¹⁰ is optionally substituted by 1 to 2 substituents independently selected from hydroxyl, halogen and C₁₋₄ alkyl; L³ is selected from a bond, C₃₋₇ cycloalkyl, C₄₋₇ heterocycloalkyl, C₄₋₇ cycloalkenyl, C₄₋₇ heterocycloalkenyl, phenyl, and C₅₋₆ heteroaryl; R⁰ is selected from hydrogen, hydroxyl, halogen, oxo, nitrogen, -N = CHN (CH₃) ₂, C₁₋₆ alkyl, C₁₋₄ haloalkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ alkoxy, C₄₋₆ heterocycloalkyloxy, -C (O) R⁶, -NR²ᵃR²ᵇ, -NR⁵C (O) R⁶, -NR⁵S (O) ₂R⁸, -S (O) ₂R⁸, tri-C-alkylsilyl, C₃₋₆ cycloalkyl, C₄ heterocycloalkyl ₋₆, C₃₋₆ cycloalkenyl, C₄₋₆ heterocycloalkenyl, phenyl, and C₅₋₆ heteroaryl; whenever L³ is a bond, R⁰ is not hydrogen; wherein the C alquilo alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, or C alco alkoxy of R⁰ optionally is substituted by 1-2 substituents independently selected from hydroxyl, halogen, C₁₋₄ alkoxy, trimetrisylyl alkoxy C₁₋₄, C₁₋₄ alkoxycarbonyl, -NR¹¹ᵃR¹¹ᵇ, C₁₋₄ alkoxycarbonylamino, C₅₋₆ heterocycloalkyloxy, C₃₋₇ cycloalkyl, C₅₋₆ heterocycloalkyl, phenyl and C y heteroaryl, wherein C₃₋₇ cycloalkyl, C₅₋ heterocycloalkyl ₆, phenyl or the C₅₋₆ heteroaryl substituent is further optionally substituted by hydroxyl, halogen, C₁₋₄ alkyl or C₁₋₄ alkoxycarbonylamino, and wherein R¹¹ᵃ and R¹¹ᵇ are independently hydrogen or C₁₋₄ alkyl; C hetero heterocycloalkyloxy, C₃₋₆ cycloalkyl, C₄₋₆ heterocycloalkyl, C₄₋₆ heterocycloalkenyl, phenyl or C₅₋₆ heteroaryl of R⁰ is optionally substituted with 1 to 4 substituents independently selected from hydroxyl, halogen, oxo, C₁ alkyl ₋₄, C₁₋₄ hydroxyalkyl, C₁₋₄ haloalkyl, - (CH₂) ₀₋₄NRᵃRᵇ, C₅₋₆ aryl-C₁₋₄ alkyl, C₄₋₆ heterocycloalkyl-C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkoxycarbonyl , amino, C₁₋₄ alkylamino, C₁₋₄ alkylsulfonyl, C₄₋₆ heterocycloalkyl, wherein Rᵃ and Rᵇ are each independently hydrogen, C₁₋₄ alkyl or C₃₋₆ cycloalkyl; R²ᵃ is selected from hydrogen, C₁₋₄ alkyl, C₁₋₄ alkoxy-C₁₋₄ alkyl, C₁₋₄ alkylcarbonyloxy-C₁₋₄ alkyl, and a C₅₋₆ heteroaryl substituted by C₁₋₄ haloalkyl; R²ᵇ is selected from hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₄ aminoalkyl, C₁₋₄ alkoxycarbonyl, C₃₋₆ cycloalkyl, C₄₋₆ heterocycloalkyl, C₅₋₆ heterocycloalkenyl, and C₅₋₆ heteroaryl, in wherein C₁₋₆ alkyl of R²ᵇ is optionally substituted by C₁₋₄ alkoxy, amino, C₁₋₄ alkylamino, C₄₋₆ cycloalkyl, C₄₋₆ heterocycloalkyl, phenyl or C₅₋₆ heteroaryl, wherein C₄₋₆ cycloalkyl, heterocycloalkyl C₄₋₆, phenyl or the C₅₋₆ heteroaryl substituent is optionally substituted by hydroxy, halogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, or C₁₋₄ alkyloxycarbonylamino; the C₄₋₆ heterocycloalkyl, C₅₋₆ heterocycloalkenyl or C₅₋₆ heteroaryl of R²ᵇ is optionally substituted by 1 to 2 substituents independently selected from C₁₋₄ alkyl and C₁₋₄ haloalkyl; R⁵ is hydrogen or C₁₋₄ alkyl; R⁶ is selected from hydrogen, C₁₋₆ alkyl, C₁₋₆ hydroxyalkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₁₋₄ alkoxy, C₁₋₆ haloalkoxy, cycloalkoxyl
priorityDate 2013-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394834
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425193155
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454973655
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458399663
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458396411
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID947
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559591
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419556970
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458396401
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID783
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457655803
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458397310
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458392451
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419579030
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID222
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394811
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID167583

Total number of triples: 46.